Roland Walter, MD, PhD
Treatment advancements for patients with acute myeloid leukemia (AML) are few and far between with marginal gains being made in the form of changes in current standard therapies or supportive care. However, several promising targeted therapies have demonstrated impressive results in early clinical trials, with the FLT3 inhibitors representing the most promising approach. Moreover, strong initial data has been generated in studies exploring immunomodulatory agents and BCL-2, IDH2, and XPO1 inhibitors, which bodes well for the continued introduction of novel AML therapeutics in the near future.
“Over the last 40 years, we have made incremental progress in the treatment of patients with AML, primarily in younger individuals,” explained AML researcher Roland Walter, MD, PhD, of the clinical research division, Fred Hutchinson Cancer Research Center, Seattle, Washington. "However, this progress is largely due to improvements in supportive care rather than the introduction of many new agents.”FLT3 Inhibitors Generate Early Excitement
To date, FLT3 inhibitors are the furthest along the clinical pipeline of the novel treatments for AML, although none has yet received FDA approval. Activating mutations in the FLT3
gene occur in approximately 30% of patients with AML, either as internal tandem duplications (ITD) or as point mutations in the tyrosine kinase domain (TKD). FLT3/ITD is more common (~25%) and has been associated with early relapse and poorer survival. The effect of FLT3/TKD mutations on patient prognosis is less clear; however, they may represent an important mechanism of resistance to FLT3 inhibitors.1
Results of a phase II trial of the FLT3 inhibitor quizartinib were presented at the 2014 ASCO Annual Meeting.2
Trial participants, who had relapsed or had refractory FLT3/ITD-positive AML, achieved a composite complete remission (CRc) rate of 47%. The most common adverse events (AEs) reported were diarrhea (18%), febrile neutropenia (16%), and prolonged QT (15%).
Sorafenib has been found to also be a FLT3 antagonist, in addition to inhibiting VEGFR, PDGFR, and Raf. It is approved for use in hepatocellular carcinoma, renal cell carcinoma, and radioactive iodine-refractory differentiated thyroid cancer. Additionally, the treatment has shown clinical activity in a small study of 6 patients with FLT3/ITD-positive AML.3
Crenolanib, a second-generation FLT3 inhibitor now in a phase II trial (NCT01657682), has demonstrated activity against FLT3/ITD and several drug-resistant mutations,4
potentially adding to the arsenal of compounds available.Orphan Drug Designation Given to XPO1 Inhibitor
Selinexor (KPT-330) is an inhibitor of the nuclear export protein exportin 1 (XPO1/CRM1), and has demonstrated activity against CLL cells ex vivo.5
Inhibition of nuclear export is thought to kill malignant cells by forcing the nuclear localization and activation of tumor suppressor proteins such as p53.
Selinexor is in phase I trials for several different cancer types. Results from a trial involving patients with relapsed or refractory AML were presented at the 2014 ASCO Annual Meeting. Forty-eight patients were given selinexor at 5-dose levels (16.8-55 mg/m2
), and no dose-limiting toxicities were encountered. Thirty-two of the patients completed cycle 1 of the trial, and 9 of these (28%) had at least a partial response to the drug.6
The FDA has given an orphan drug designation to selinexor for the treatment of AML, potentially accelerating its path to the clinic.Antibody-Drug Conjugates Rejuvenated
The antibody-drug conjugate (ADC) gemtuzumab ozogamicin (GO) is made up of a toxin (calicheamicin) linked to an antibody directed against the CD33 cell surface antigen. Although it was approved for use in refractory/relapsed AML, a combination of ineffectiveness in many patients plus excessive AEs resulted in its withdrawal from the market. More recent trials with different populations have again shown positive results with this drug, resulting in calls from some researchers for its reintroduction.7
Regardless of the ultimate fate of GO, it has shown the potential for therapies using antibodies targeting CD33, and a new CD33-targeting ADC, SGN-CD33A, is in a phase I clinical trial (NCT01902329).Bispecific T-cell Engager Antibodies
Bispecific T-cell engager (BiTE) antibodies are chimeric combinations of 2 different antibodies. One of the antibodies is directed against the CD3 antigen of cytotoxic T-cells, while the second targets an antigen on the malignant cell, thereby engaging the patient’s own immune system in clearing the leukemia.